United Kingdom · Question · Written question
UIN 126525
Tixagevimab/cilgavimab
Introduced
18 January 2023
Last action
24 January 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
24 January 2023
Summary
To ask the Secretary of State for Health and Social Care, what criteria his Department uses to assess the cost-effectiveness of the use of Evusheld against the cost of admission to a hospital for an immune-compromised person with complex health conditions
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
18 January 2023
Written question
To ask the Secretary of State for Health and Social Care, what criteria his Department uses to assess the cost-effectiveness of the use of Evusheld against the cost of admission to a hospital for an immune-compromised person with complex health conditions
Source: Commons
24 January 2023
Answer
The Department has asked the National Institute for Health and Care Excellence (NICE) as the independent expert body to develop guidance for the National Health Service on the clinical and cost effectiveness of Evusheld in its licensed indications for the...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-01-18/126525
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1568139
- uk · wq-1568139 · source updated 24 January 2023